SUVEN360.00

Suven Life Sciences Limited

· Pharma & Health
₹ CrorePeersVIMTALABSTAKEMcap ₹9,494 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity-38.91-146.15-46.73-46.73
Return on Assets-36.88-118.91-44.27-44.27
Return on Capital Employed-49.56-153.63-48.90-48.90
Return on Invested Capital-74.37-236.09-49.75-63.91
Margins
EBITDA Margin-1,094.72-2,490.66-3,998.80-4,155.50
Operating Margin-1,150.33-2,578.13-4,077.70-4,077.70
Incremental Operating Margin736.30-25,827.22
Pretax Margin-907.21-2,415.11-3,884.13-3,998.70
Net Income Margin-898.63-2,415.11-3,884.13-3,998.70
FCF Margin-685.86-2,875.39-4,313.18-4,313.18
Additional
Effective Tax Rate0.940.000.00-0.00
Sustainable Growth Rate-38.91-146.15-46.73-46.73
Incremental Operating Margin %736.30-25,827.22-4,857.93
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.